Page last updated: 2024-11-04

vorinostat and Takotsubo Cardiomyopathy

vorinostat has been researched along with Takotsubo Cardiomyopathy in 1 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Takotsubo Cardiomyopathy: A transient left ventricular apical dysfunction or ballooning accompanied by electrocardiographic (ECG) T wave inversions. This abnormality is associated with high levels of CATECHOLAMINES, either administered or endogenously secreted from a tumor or during extreme stress.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Khurana, I1
Maxwell, S1
Royce, S1
Mathiyalagan, P1
Karagiannis, T1
Mazarakis, N1
Vongsvivut, J1
K N, H1
Okabe, J1
Al-Hasani, K1
Samuel, C1
El-Osta, A1

Other Studies

1 other study available for vorinostat and Takotsubo Cardiomyopathy

ArticleYear
SAHA attenuates Takotsubo-like myocardial injury by targeting an epigenetic Ac/Dc axis.
    Signal transduction and targeted therapy, 2021, 04-20, Volume: 6, Issue:1

    Topics: Acetylation; Animals; Disease Models, Animal; Epigenesis, Genetic; Mice; Takotsubo Cardiomyopathy; V

2021